Asset
Imapextide
MBX Biosciences Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06036784 | phase1 | completed | 2023-09-18 | 2024-11-14 | MBX Biosciences | Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects |
| NCT07029412 | phase2 | completed | 2025-08-26 | 2026-04-18 | MBX Biosciences | Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI) |
FDA applications (0)
This company has no applications containing this asset.